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ABSTRACT 
 
After decades of work, the correct determination of the binding mode of a small 
molecule into a target protein is still a challenging problem, whose difficulty depends 
on: i) the sizes of the binding site and the ligand; ii) the flexibility of both interacting 
partners, and iii) the differential solvation of bound and unbound partners. We have 
evaluated the performance of standard rigid(receptor)/flexible(ligand) docking 
approaches with respect to last-generation fully flexible docking methods to obtain 
reasonable poses in a very challenging case: soluble Epoxide Hydrolase (sEH), a 
flexible protein showing different binding sites. We found that full description of the 
flexibility of both protein and ligand and accurate description of solvation leads to 
significant improvement in the ability of docking to reproduce well known binding 
modes, and at the same time capture the intrinsic binding promiscuity of the protein. 
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1. Introduction 
 
Accuracy in predicting how a small molecule binds to its target is an essential 
requirement for structure-based drug design (SBDD). The correct pose prediction of a 
small molecule in a binding site allows gaining insight on which chemical features are 
essential for achieving its biological activity,1,2 and using this information to improve 
the properties of the lead compound. In principle, the binding mode of ligands can be 
obtained by means of experimental techniques, but the time-restrictions in practical 
drug design projects are often incompatible with X-Ray and NMR time scales, forcing 
the use of computational approaches, particularly of docking algorithms.3  
 
Current docking methods are typically based on a rigid receptor around which a ligand 
is rotated, translated and flexed until the best fit is found. Although docking has been 
proven to be an extremely useful tool,4 it yields suboptimal results in cross-docking 
experiments, i.e when one ligand is docked to the image of the receptor that is either 
unbound, or bound to a significantly different ligand.5 Bearing in mind that most 
macromolecular targets undergo some kind of induced-fit upon binding,6 the number of 
cases where standard docking procedures find problems is not negligible. 
 
A simple strategy to model the flexibility of the macromolecular receptor is to submit it 
to a molecular dynamics (MD) simulation, from which a series of relevant 
conformations for rigid docking are derived.2,3 Although this might mitigate the 
negative impact of the rigid receptor approximation, plain MD does not usually provide 
sufficient protein conformational sampling, and there are not clear rules to extract a 
subset of representative configurations from the crude ensemble.7 Similar or even larger 
problems arise when protein models for docking are obtained from experimental 
ensembles.8 Alternative strategies to ensemble docking arise from the use of Induced-Fit 
Docking algorithms.  One such approach is based on the iterative combination of rigid 
receptor docking plus protein structure prediction for certain areas of the active site.9 
This method has proven to be especially relevant for detecting significantly large 
conformational transitions upon ligand binding, such as the kinase DFG-in/out 
conformational change.9 However, in general, solving the flexibility problem requires 
direct coupling between conformational exploration and binding, which in principle can 
be achieved by brute force molecular dynamics algorithms.10 Unfortunately, these 
calculations are still in the proof-of-concept stage requiring highly specialized computer 
resources which are rarely accessible to standard drug-design laboratories. Use of biased 
MD simulations can reduce the cost of calculations, but they are still too expensive and 
requires a previous knowledge of the expected binding mode,11 something uncommon in 
the practical drug design scenario. 
 
A few intermediate methods aiming to couple docking with conformational transitions, 
but escaping from the complexity of brute force MD simulations have been suggested. 
For example, in the essential dynamics molecular dynamics (ED/MD) approach the 
protein dynamics in the essential deformation space is coupled with sampling of ligand 
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degrees of freedom in the Cartesian space12,13 allowing a coupled sampling of protein 
and ligand flexibilities. Medusadock,14 models receptor and ligand flexibility 
simultaneously by using sets of discrete rotamers and RosettaLigand15 allows docking 
ligands to receptors by using a Monte Carlo minimization procedure in which the rigid 
body position and orientation of the small molecule and the protein side-chain 
conformations are optimized simultaneously.16 Finally, PELE (Protein Energy 
Landscape Exploration)17-22 implements a Metropolis Monte Carlo algorithm, where 
new trial configurations are produced for both ligand and protein while docking is 
performed. The program implements side chain prediction algorithms, specific ligand 
rotamer libraries, implicit solvent model,23 and all-atom OPLS2005 force field24 to 
compute receptor-ligand interactions. 
 
We explore here the performance of two state-of-the-art docking methods: GLIDE, 
based on the traditional paradigm of a rigid receptor and a flexible ligand, and PELE, a 
fully flexible approach. Of note, for the rigid receptor approximation, both standard 
docking against a series of experimental X-ray structures and docking against two MD-
generated ensembles are tested. The benchmark system selected was Soluble Epoxide 
Hydrolase (sEH, Fig. 1a,b), an enzyme that metabolizes epoxyeicosanoic acids (EETs) 
generating products that have been linked to a variety of therapeutic areas, such as 
inflammation, pain and hypertension.25 This protein was chosen, not only for its 
potential pharmacological interest, but because of its novelty (structural data on this 
protein were not available when GLIDE or PELE were developed) and its complexity, 
since it shows26,27 a complex binding site characterized by a huge hourglass-shaped 
binding cavity with the catalytic residues in a center channel separating a left-hand site 
(LHS) from a right-hand site (RHS), both able to bind ligands.26,27 The combination of 
high flexibility and complexity of the binding cavity (divided in 3 different sub-cavities) 
makes sEH an extremely challenging benchmark for docking approaches.  
 
Figure 1. 
a)                                 b) 
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Results presented here confirm the power of standard docking approaches (exemplified 
by GLIDE) but also their caveats. It is found that generating an ensemble of 
conformations via MD can in some instances improve the results as compared to using 
only an X-ray structure. However, for this challenging system it is found that 
representing both small molecule and protein flexibility simultaneously is crucial in 
order to have reasonable poses, to discriminate between alternative binding sites and to 
derive poses that can be useful for further lead optimization studies. In this sense, the 
use of fully flexible methods as PELE provides much improved results. 
 
Figure 2. 
a) 
 
b)     c) 
 
 
d) 
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2. Methods and computational details 
 
More than  90 structures of human sEH are deposited in the PDB. A recently deposited 
one (PDB entry 5AHX) corresponds to the apo structure, while a variety of  other 
crystals correspond to complexes with ligands of different sizes bound to different 
subcavities. For our docking experiment we selected 20 of these ligands based on 
diversity criteria (see Figure 2) and cross-docked them to 6 protein structures 
corresponding to the unbound apo structure (5AHX) and 5 bound states (see Figure 2) 
selected to cover the different binding modes of the protein (5AI0, 5AIC, 5AKE, 5ALY 
and 5ALO). Additionally, for the MD-ensemble approach, a series of protein 
conformations were generated by standard molecular dynamics simulations for the apo 
structure (5AHX) and also for the complex of sEH when bound to Fulvestrant (4J03), 
an anti-cancer agent that was serendipitously found to be a potent sEH inhibitor (see 
Figure 2).  All the protein models were prepared for further calculations using the 
Protein Preparation Wizard (PPW) tool of Schrödinger software28,29 thus building any 
incomplete sidechains, optimizing the hydrogen bond network and predicting the 
protonation states of all His, Asp, Glu, Lys, and Arg sidechains. Solvent molecules were 
removed in all cases, as well as any other molecules that might be present from the 
crystallization buffers. 
 
2.1. CMIP calculations 
 
Classical molecular interaction potentials (CMIP using Na+ and CH4 as probes;30) were 
used to define the recognition characteristics of sEH binding site. The electrostatic term 
in CMIP was obtained by solving the non-linear Poisson Boltzman equation31 (with 
standard protein and solvent dielectric definition, while the steric terms were accounted 
for by van der Waals formalism using standard AMBER parameters.30 
 
2.2. Standard docking  
 
Standard docking calculations (rigid target, flexible ligand) were performed using 
GLIDE, one of the most validated docking programs in the field.32-34 GLIDE grids were 
centered on catalytic triad residue D335, and extended to cover the whole binding site. 
Standard defaults for grid creation and ligand flexible SP (Standard Precision) docking 
were used. 
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2.3. MD-generated ensembles 
 
In order to complete the comparison between fully flexible PELE simulations and 
rigid(receptor)/flexible(ligand) calculations with GLIDE against a series of X-ray 
structures, two MD generated ensembles were also tested. One of them was extracted 
from a 200 ns. MD trajectory of the apo structure (5AHX). The second was extracted 
from a 200 ns. MD trajectory of the holo structure of sEH when bound to Fluvestrant, 
which is an anti-cancer agent found to be a potent inhibitor of sEH and which, because 
of its big size (see Figure 2d), binds the enzyme occupying all LHS, channel and RHS 
subsites. 
Molecular dynamics simulations of the two systems were performed with AMBER1435   
and the ff14SB force field. Explicitely solvated (TIP3P waters)36 systems were 
simulated in the NPT ensemble in a truncated octahedron box. Sodium and chlorine 
ions were added to simulate physiological ionic strength and to bring the total charge to 
neutrality. The lid portion of sEH was removed in all simulations. SHAKE37  was used 
to constrain chemical bonds, which allowed us to use an integration step of 2fs.  For 
Fulvestrant, RESP charges were calculated at HF/6-31G** level together with GAFF38 
parameters. Total production runs of 200 ns were collected, with snapshots saved every 
20 ps. All analyses from the simulations were carried out  with CPPTRAJ39. The 
clustering and extraction of snapshots for the simulations was performed by a 
hierarchical agglomerative algorithm and average-linkage method based on Cα pair-
wise distances. After clustering, a representative set of 4 snapshots from the first 4 most 
populated clusters were taken for each of the two simulations and used for the ensemble 
rigid(receptor)/flexible(ligand) docking calculations. 
 
2.4. PELE simulations 
 
PPW-refined protein was manipulated to reduce its size by removing the lid region (Fig. 
1a), which helped us to reduce the cost of calculations. The ligands under study were 
placed outside the protein at distances of around 20 – 25 Å RMSd away from the 
binding site, and an approximate distance of 3 – 5 Å to the loop K495-V500 (the 
selected position gives approximately equal access for entering and exploration of the 
LHS and RHS). For each simulation a sphere with center around the catalytic residue 
D335 and radius of 14 to 18 Å was used to limit the exploration to the approximate area 
of the sEH active site.  
 
Following standard PELE use, the ligand originally placed at a random position is 
translated and rotated, and the protein is perturbed following the normal modes of lower 
frequency. In a further step, the complex is readapted, eliminating possible tensions 
produced in the perturbation step by performing a side chain prediction and full 
minimization. The resulting structure is accepted or rejected following the Metropolis 
criterion.  
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Ligand perturbation was switched between two modes of translation: a large one of 3.0 
Å (when the ligand is far from the protein based on ligand SASA), and a small one of 
0.5 Å (when the ligand is close to the protein). Along with the translation, the ligand 
was randomly rotated (rigid body rotation) in the range 0-15°. Backbone movements 
were performed by moving along the first six modes calculated from an elastic 
deformation model.40 This was accomplished by performing an all-atom geometry 
optimization, where a constraint is added to each alpha carbon along a randomly chosen 
mode (with displacements of 1.0 Å). Finally a relaxation was accomplished with a 10° 
resolution side chain sampling for those residues having at least one atom within a 4 Å 
distance of any ligand atom (a 30° step was used for the ligand rotatable bonds).18 The 
final minimization included a weak constraint (1.0 kcal/mol/Å) every 10 alpha carbons, 
which help to avoid compaction of the protein due to the lack of explicit solvent (more 
details about PELE and setting up the simulations can be found at https://pele.bsc.es). 
 
3. Results 
 
3.1. Binding site analysis 
 
As shown in Figure 1 most of the backbone flexibility in the sEH binding site is located 
in a few loops, namely those composed by amino acids N368-P379 (which make up part 
of the “ceiling” of the LHS), amino acids A411-M419 (which make up the whole of the 
ceiling of the RHS) and to a lesser extent, to the loop composed by K495-V500 (which 
is placed in the middle of the structure, lining a side of the central channel). These loop 
movements are responsible for most of the active site changes in volume and 
recognition. However, even with very slight backbone displacements, the subsites 
change in shape and recognition due also to a variety of side chain movements. When 
the X-ray structures of the complexes are superimposed, especially relevant side chain 
flexibility movements are seen for residues M310, W336, M339, Y343, I363, I375, 
Q384, M469 in the LHS and residues L408, L417, M419, V498 in the RHS. Of note, 
most of these residues are mainly big and hydrophobic, a feature that is line with the 
nature of the endogenous substrates of sEH (for an example, see Figure 2b), which are 
flexible carboxylic-acid bearing metabolites characterized by long aliphatic chains.  
 
The mainly hydrophobic nature of the active site can be perceived in the CMIP profiles 
obtained for the +1 charged probe particle in the case of the apo structure of the 
enzyme. As can be seen in Figure 3a, most of the favorable interaction points are 
basically located in the central channel, where the catalytic triad (D335, Y383, and 
Y466) is found. This means that, as suspected, hydrophobic and van der Waals 
interactions will have a strong impact in the biological activity of the inhibitors binding 
either LHS or RHS. Of note, this analysis was replicated for a series of holo structures 
finding very close results in all cases.   
 
In order to better perceive the induced fit effects of sEH in the different subsites, a 
series of CMIP calculations were carried out with the goal of comparing the three 
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binding pockets. The adaptation of the protein subsites to the presence of some of the 
inhibitors found in Figure 2 was tested. As a sample, three of them are discussed herein 
– 5ALT, 5ALY and 5ALS as representatives of LHS, RHS and Channel pockets, 
respectively. As seen on Figure 3, 5ALT and 5ALY are characterized by a lack of 
favorable vdW interactions (closed channel) in the catalytic triad region compared to 
5ALS structure where a thin surface joins RHS with LHS is found.  In 5ALT the RHS 
vdW surface is comparable in size to the LHS, the last is mainly formed by 4 
hydrophobic and flexible sidechains of M310, M339, M469, I363 plus W336. CMIP 
calculations for the representative of the RHS complexes (5ALY, Fig. 3b) show better 
options for hydrophobic interactions in the right pocket. The main residue that increases 
the surface of RHS in 5ALY compared to 5ALT (and also changes frequently its 
position in the different crystals via induced-fit movements) is M419, while I363 and 
I375 make the difference between 5ALT and 5ALY in the LHS. The Channel 
representative – 5ALS (Fig. 3d) displays a clear shift and an opening movement of the 
entire K495-V500 loop and the formation of the channel “tube” together with a new 
hydrophobic pocket around F381.  
 
In summary, this binding site analysis clearly underlines the plasticity of the each of the 
three subsites of sEH, which can adapt their conformation to the bound ligand by 
varying backbone and side chain conformations. The different subsite conformations are 
clearly incompatible for binding molecules other than the ones they were crystallized 
with. This picture translates, as could be expected, in a tough system for ligand pose 
prediction by rigid docking techniques (see below).  
 
Figure 3. 
       a)                                                             b) 
 
        c)                                                            d)                       
     
 
3.2 Binding mode prediction by standard docking against X-ray structures 
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Both HTS and NMR-based screening experiments found an extremely high degree of 
hits for sEH, suggesting a large promiscuity probably related to its large and 
hydrophobic binding site. Very encouragingly, GLIDE is able to capture the “sticky” 
nature of the protein. Encouragingly, all the inhibitors considered (Figure 2a) appear as 
hits in the standard docking experiments. However, when going to a more detailed 
analysis less brilliant results emerge (see Table 1, Fig. 4) as across the 120 (20 ligands 
vs 6 protein structures) pairs calculated, only 19 top scoring poses are below 3.0 Å in 
RMSd (from the experimental binding pose), the number successes being reduced to 6 
if the RMSd threshold is reduced to 2 Å).  
 
Table 1 
Glide SP cross-docking results for the set of 20 ligands (Figure 2a) against the 6 protein 
structures (Figure 2c). RMSd of the top scored pose / best RMSd amongst the top five 
scored poses are given when compared to the experimental pose. The ligand-protein 
pairs for the selected complexes chosen for subsequent PELE simulations are shown in 
bold. 
 
Protein 
PDB 
entry 
 
 
Ligand PDB entry 
 
5AI5 5AIC 5AKE 5AKG 5AKH 5AKJ 5AKL 5AKY* 5ALD 5ALE 
           
5AHX 1.5/1.4 3.1/3.1 2.9/2.8 15.3/5.7 1.5/1.5 7.2/7.2 10.4/10.1 2.1/2.1 2.5/2.5 1.0/1.0 
5AI0 7.3/6.8 4.6/2.8 13.2/3.2 6.4/5.8 13.0/12.8 5.5/5.5 10.5/10.1 4.7/2.8 2.2/2.2 2.2/0.7 
5ALX 7.6/7.1 11.1/3.0 10.9/10.9 6.3/5.7 12.2/12.2 8.6/5.9 9.9/9.8 2.7/2.3 11.8/5.7 11.3/1.0 
5ALO 6.9/6.8 11.4/10.3 9.8/3.0 6.4/5.3 12.9/12.6 7.9/8.0 10.6/10.3 7.1/4.3 11.4/11.4 11.8/11.4 
5AKE 0.8/0.4 9.5/5.0 2.5/2.4 7.0/5.3 13.5/11.2 6.3/1.2 1.4/1.4 3.7/3.7 3.0/3.0 5.7/5.7 
5AIC 7.8/6.7 10.5/4.6 12.8/3.0 6.2/5.4 13.5/13.1 8.7/8.3 10.9/10.2 5.4/2.5 2.3/2.3 1.2/1.2 
           
 
Protein  
PDB 
entry 
 
 
Ligand PDB entry 
 
5ALK 5ALL 5ALM 5ALS 5ALT 5ALW 5ALY 5AM0 5AM4 5AM5* 
           
5AHX  13.1/12.8 3.3/3.2 6.4/1.5 7.5/7.5 14.8/14.6 15.3/5.5 6.5/3.9 5.7/4.4 4.1/2.1 2.0/2.0 
5AI0 13.3/12.4 4.0/4.0 6.8/5.6 8.1/8.1 14.9/13.9 6.0/5.6 4.4/4.4 3.7/3.7 2.0/1.6 2.1/1.6 
5ALX 12.9/12.3 9.9/9.8 5.1/5.4 8.0/7.9 14.8/3.3 15.5/13.5 15.3/13.8 12.8/12.6 14.2/14.2 6.7/5.5 
5ALO 12.8/12.1 8.9/8.9 6.3/5.8 10.8/10.3 4.6/4.6 15.6/6.0 12.1/12.1 12.3/11.9 14.3/4.0 5.2/5.0 
5AKE 12.3/12.7 4.2/4.2 4.9/3.8 2.1/2.1 14.7/6.1 8.7/4.5 12.2/12.3 12.0/12.0 13.3/12.9 6.1/6.0 
5AIC  
 
12.6/12.4 10.2/9.8 6.2/4.8 11.8/11.8 14.9/14.2 14.4/6.0 13.9/13.7 3.4/3.4 15.4/14.6 1.7/1.6 
* – only the best result from both pockets LHS and RHS is shown 
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Figure 4. 
a)                                             b) 
 
 
The problem is not related to small errors in the scoring function, as the results do not 
improve dramatically if not only the 1st, but the five best scored posed are considered 
(see Table 1). In fact, for many ligands such as those appearing in 5AKG, 5AKJ, 5ALK, 
5ALL or 5ALM (to name a few) it is impossible to find a reasonable binding mode 
when docked against any of the 6 structures of sEH considered. Likewise, GLIDE has 
severe problems finding correct binding modes for some protein conformations. For 
example, for 5ALO no ligand could be cross-docked correctly, for 5ALX only one is 
successfully cross-docked. Quite surprisingly, the apo structure seems to be among the 
best in accommodating more ligands (see 5AHX in Table 1), suggesting that when the 
protein adapts its structure to a given ligand it adopts a conformation that does 
recognize well many other compounds. This is confirmed by the fact that dual binding 
modes (for example 5AM5 and 5AKY) are not successfully recovered in GLIDE cross-
docking experiments (see Table 1). 
 
In summary, despite the general success of standard docking procedures (exemplified 
by GLIDE) to recognize potential ligands of sEH, binding poses are wrong in several 
cases, providing structural information which can mislead lead optimization procedures 
(see for instance Fig. 4). It seems that significant protein relaxation is coupled to the 
effective binding of ligands, which clearly reduces the success of standard docking 
procedures. 
 
3.3 Binding mode prediction by standard docking against an MD-generated 
ensemble  
 
As a further test of what can be expected from the rigid(receptor)/flexible(ligand) 
docking approach, it was decided to take a small ensemble of structures generated from 
MD simulations, to see if the results against X-ray structures could be improved by 
adding additional conformations of the protein. To this end, 2 MD simulations were 
carried out. One of them was that of the apo structure deposited in the pdb (5AHX). The 
second was the holo structure of sEH in complex with Fulvestrant (4J03).41 This 
complex was especially interesting as this is a big drug whose binding mode implies 
occupying all three subsites. From each of the 2 simulations, 4 representative snapshots 
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were used for docking the 20 compounds found in Figure 2a. The results are 
summarized in Table 2. Its analysis reveals a series of points.  
 
The crystal structure 4J03, in line with the crystal structures featured in Table 1 above, 
seems to be able to recapitulate a small number of correct poses (only 3 ligands are 
placed under 3 Angstroms RMSd from their native poses as top scored). Encouragingly, 
when the ensemble of MD-derived structures (4J03_1 to 4J03_4) is taken instead of the 
single X-ray, the results improve for a few cases (see for instance 5AKE, 5AKL, 5ALL 
and 5ALS, where at least one MD-snapshot does indeed recapitulate the correct binding 
mode as top pose). However, it must be borne in mind that in some cases (for instance 
5ALM) the ensemble seems to be worse than the X-ray structure.  
 
A poorer performance is seen for the MD-generated ensemble of the apo structure 
(5AHX_1 to 5AHX_4). Not a single miss of its X-ray structure is recapitulated by the 
MD-ensemble, and discouragingly some of the ligands found to dock correctly on the 
X-ray are totally missed by the ensemble (see for instance 5AKE, 5AKH, 5ALE or 
5AM5).  
 
 
Table 2 
Glide SP ensemble docking results for the set of 20 ligands (Figure 2a) against sEH 
structures derived from 2 MD simulations. 4 representative snapshots extracted from 
each of the MD trajectories of 5AHX and 4J03 were used (identified as 4J03_1 to 
4J03_4 and 5AHX_1 to 5AHX_4). RMSd of the top scored pose / best RMSd amongst 
the top five scored poses are given when compared to the experimental pose. 
 
Protein 
structure 
 
 
Ligand PDB entry 
 
5AI5 5AIC 5AKE 5AKG 5AKH 5AKJ 5AKL 5AKY* 5ALD 5ALE 
           
4J03 1.4/0.6 4.7/4.7 3.3/3.3 6.6/6.3 5.7/4.8 2.0/1.3 7.5/1.5 6.1/1.8 9.8/7.1 5.0/5.0 
4J03_1 1.6/1.6 10.3/8.9 9.0/9.0 7.9/7.7 13.1/11.7 1.2/1.1 10.3/9.5 5.2/5.2 11.2/10.3 5.0/5.0 
4J03_2 1.4/0.9 9.1/9.1 8.9/8.8 13.5/9.9 14.6/12.4 1.5/1.0 8.0/7.9 5.4/5.4 12.7/10.2 5.0/5.0 
4J03_3 1.5/1.4 8.7/7.7 2.6/2.6 14.1/7.1 13.6/11.1 2.5/1.3 1.00/0.7 4.9/4.8 12.0/5.8 4.8/4.8 
4J03_4 1.4/1.4 11.8/3.1 2.8/2.8 6.6/6.5 14.4/6.2 6.7/6.1 12.2/11.2 6.1/6.0 7.6/4.1 7.3/2.9 
5AHX 1.5/1.4 3.1/3.1 2.9/2.8 15.3/5.7 1.5/1.5 7.2/7.2 10.4/10.1 2.1/2.1 2.5/2.5 1.0/1.0 
5AHX_1 6.6/6.4 11.1/10.1 3.4/3.3 6.8/6.3 13.6/11.4 6.7/6.7 11.8/10.6 7.0/2.9 10.6/10.4 10.8/10.4 
5AHX_2 1.3/1.2 5.0/3.3 13.3/13.1 16.0/7.1 14.1/12.7 8.1/7.8 1.4/1.4 6.2/4.6 14.4/13.9 2.6/2.6 
5AHX_3 2.3/2.0 14.9/10.6 10.0/10.0 13.8/6.3 15.6/13.5 5.2/5.2 11.2/10.8 6.3/4.7 14.3/12.2 6.0/6.0 
5AHX_4 5.7/5.6 11.9/4.6 9.7/9.5 15.0/7.3 12.5/5.3 5.0/4.1 10.1/10.1 5.9/3.8 12.4/3.7 4.6/4.6 
           
 
Protein 
structure 
 
 
Ligand PDB entry 
 
5ALK 5ALL 5ALM 5ALS 5ALT 5ALW 5ALY 5AM0 5AM4 5AM5* 
           
4J03 15.1/14.9 9.9/1.0 2.2/1.3 8.4/2.8 13.1/12.0 8.2/5.7 7.0/7.0 14.5/12.0 3.2/3.2 7.3/4.8 
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4J03_1 14.4/11.3 10.6/7.8 8.2/4.2 11.5/6.5 6.6/6.6 8.3/8.3 12.3/10.6 12.8/12.4 12.5/12.1 6.0/5.7 
4J03_2 10.6/9.7 2.3/2.3 7.8/5.8 2.1/2.1 7.1/6.3 8.3/7.8 12.1/10.6 11.8/11.2 12.5/12.2 6.6/6.6 
4J03_3 13.3/13.1 7.4/7.4 8.8/2.9 2.3/2.3 14.3/10.8 13.5/6.8 12.2/7.2 11.6/11.6 14.2/14.0 6.1/5.6 
4J03_4 16.9/14.1 1.1/0.9 9.6/9.3 9.9/9.9 12.2/12.0 4.7/4.7 5.2/4.6 4.7/3.6 3.8/3.5 5.9/5.5 
5AHX  13.1/12.8 3.3/3.2 6.4/1.5 7.5/7.5 14.8/14.6 15.3/5.5 6.5/3.9 5.7/4.4 4.1/2.1 2.0/2.0 
5AHX_1 11.1/11.1 9.8/8.6 5.3/5.3 9.1/3.5 5.9/5.9 13.8/13.3 15.1/14.5 12.3/11.4 13.2/13.1 4.9/4.9 
5AHX_2 12.4/12.4 5.0/2.7 9.0/8.4 9.2/8.4 3.9/3.7 14.4/12.4 15.8/11.7 11.7/11.7 15.0/14.8 5.4/5.4 
5AHX_3 14.5/13.1 11.3/9.8 8.4/8.1 13.6/12.5 12.3/6.6 14.8/12.0 15.4/15.4 14.3/14.0 15.4/15.2 5.9/4.8 
5AHX_4 5.5/5.0 10.6/3.2 9.8/8.7 4.9/4.9 13.0/13.0 4.0/4.0 15.4/6.3 4.9/4.6 13.3/5.3 5.3/5.3 
           
* – only the best result from both pockets LHS and RHS is shown 
In summary, it is seen that ensemble docking against a series of MD-derived structures 
can allow recovering the correct pose for some ligands that could not be docked 
correctly against their X-ray. However, in the case ofsEH, this is only true for the holo 
structure tested, but not the apo.  Furthermore, in a significant number of cases, 
ensemble docking based on the holo structure still does not lead to correct, productive 
poses.    
 
3.4 Binding mode prediction by flexible docking 
  
A set of ligand/protein conformation pairs found in Table 1 were selected for PELE 
flexible docking calculations. These pairs (in bold in Table 1) were randomly selected 
among the “hard” cases for which standard docking fails to provide good poses, 
representing then a very difficult test set for PELE. Very remarkably, the results of the 
PELE simulation are strikingly good (Table 3 and Figure 5), since for all the cases the 
best scored pose is at less than 3 Å from the experimental one, and in more than 70% of 
the cases the RMSd between predicted (as the minimum energy structure) and 
experimental binding pose is less than 2 Å. This means that PELE provides then 
structural models of enough quality as to be useful in lead optimization procedures. 
Interestingly, in a few cases, the program finds one or two alternative solutions, distinct 
from the experimental one, which are very close in energy to the correct one, 
confirming the extreme promiscuity of this protein. 
 
Table 3 
PELE induced-fit docking results for the tough pairs highlighted in Table 1RMSd of the 
top scoring poses (lowest interaction energy poses) from the ligand PDB entry native 
ones.  
 
 
 
Ligand PDB entry/ 
Protein PDB entry 
 5AI5/ 
5ALX 
5AIC/
5AKE 
5AKE/
5ALX 
5AKG/
5AIC 
5AKH/
5AI0 
5AKJ/
5AHX 
5AKL/
5AHX 
5AKY/
5ALO 
(RHS) 
5AKY/
5ALO 
(LHS) 
5ALD/ 
5ALX 
5ALE/ 
5ALO 
            
            
RMSd 1.7 0.7 2.6 1.9 1.4 1.6 1.6 2.7 2.1 1.4 1.3 
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Ligand PDB entry/ 
Protein PDB entry 
 5ALK/
5AHX 
5ALL/
5ALX 
5ALM/
5ALO 
5ALS/
5AI0 
5ALT/
5AHX 
5ALW/
5AI0 
5ALY/ 
5AI0 
5AM0/ 
5AHX 
5AM4/
5AKE 
5AM5/
5AKE 
(RHS) 
5AM5/
5AKE 
(LHS) 
            
            
RMSd 0.9 0.8 2.9 2.4 1.6 1.9 0.5 0.8 0.8 1.5 2.5 
 
The quality of PELE-derived poses allowed us to explore the flexibility pattern involved 
in binding to the different subcavities. Thus, binding to LHS subsite (an example is the 
binding of the 5ALT ligand to the apo structure (5AHX) requires a rearrangement of the 
structure via both backbone and sidechain movements which helps to define a good van 
der Waals recognition basin (around I363, M339, F381 and W336; see Figure 6a). 
Binding to the Channel requires rearrangements in Y383, Q384 and Y466 to define a 
good binding pocket, which allows the formation of crucial hydrogen bonds to the 
catalytic triad. Without these rearrangements the ligand 5AKL is placed by docking 
procedures more than 10 Å away from its actual binding mode in a different pocket 
(Table 1), while induced fit in PELE simulations allows to recover two symmetrically 
equivalent solutions regarding the two phenyl rings of the ligand (Fig. 5b and Fig. 6b). 
Even bigger conformational changes in the channel are required for the binding of the 
5ALS ligand to the 5AI0 structure (compare Figure 5c and 6c) some of them already 
discussed in the CMIP analysis (see above). Binding of ligands to the RHS subsite is 
coupled also to some non-negligible conformational changes in the protein. For 
example, in the case of binding of 5ALK ligand to the apo structure, movements of 
M419 and V498 need to occur to define a successful binding point allowing a 
productive recognition of D496 and D335, since otherwise the ligand binds at sites that 
are located more than 13 Å away (see Table 1, Figure 5d and Figure 6d). Slightly 
different rearrangement (only V498) is required for a productive binding of the small 
ligand present in 5AIC (Figure 2a) to protein structure in 5AKE - without this change, 
different incorrect poses are recovered (Table 1, Figures 5e and 6e). Finally, dual RHS-
LHS binders (that of compounds 5AM5 and 5AKY) require dual conformational 
changes in RHS and LHS (M469 in the LHS, and V498 in RHS), since otherwise poses 
generated are incorrect (Table 1). Fully flexible methods such as PELE allow us to 
capture properly the complex conformational choreography implicit to dual binding (see 
Figures 5f and 6f). 
 
As a last note, it should also be mentioned that, in spite of the marked hydrophobic 
nature of the sEH active site, a few of the ligands partially interact with sEH via 
bridging water molecules. This is the case for instance of the 5AM5 and the 5ALT 
ligands (which bind in the LHS) and the 5ALE ligand (which binds in the RHS). As it is 
discussed above, PELE finds the correct binding mode even for these cases, although 
the program takes into account the role of solvent by an implicit solvation model, . An 
explanation for this behavior is that PELE, by way of exploring receptor and ligand 
degrees of freedom simultaneously, is able to correctly find the correct fit between 
protein and ligand in the very occluded active site ofsEH, compensating for the absence 
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of certain water molecules. It might be expected that, in cases of more open binding 
sites, explicit waters should be added into the PELE calculations. 
 
Figure 5. 
   a)                         b)     c) 
 
    d)                         e)      f) 
 
 
Figure 6. 
 
a)                                  b) 
 
c)                                  d) 
 
e)                                  f) 
 
 
4. Conclusions 
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Soluble Epoxide Hydrolase has a very malleable binding site which allows it to adapt to 
the presence of a wide range of varying chemical cores. Ligand-induced conformational 
movements lead to very significant changes in the recognition properties of the protein, 
visible in CMIP calculations, which makes the protein conformation over-specialized to 
recognize only similar ligands, failing to recognize others with a less similar structure or 
binding to alternative places of the large binding site. In this type of cases, standard 
docking approaches (rigid receptor) against an X-ray structure, which dominates the 
field of high throughput virtual screening, can be useful to retain potential binders but 
they are likely to produce reliable poses that can guide chemists to improve a lead 
compound only in a limited number of cases. This deficiency can be partially overcome 
by ensemble docking with a series of MD-derived structures, but only to a small extent 
and in case a holo structure is used. Very encouragingly, fully flexible docking methods 
such as PELE are not only able to successfully predict experimentally-determined 
binding in all the tested cases, but they are also capable of providing a fuzzy scenario of 
alternative binding modes which can provide unexpected clues to the design of 
completely new families of ligands. 
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LEGENDS TO FIGURES 
 
Figure 1. Structure of sEH. a) Catalytic (upper) and lid (lower) domains depicted with a 
B-factor ribbon (green-yellow-red spectra). The “x” denotes the site at which the lid 
region was cut to simplify the system. The ** sign is the approximate starting position 
for the ligands in the PELE simulations. b) Binding site of sEH, highlighting the LHS, 
RHS, and Channel subsites and B-factor ribbon marking the most flexible loops for 56 
PDB entries. The color coding is from green (rigid) to red (flexible).  
 
Figure 2. a) 2D Structures of the 20 compounds used for retrospective binding mode 
prediction, together with their PDB entries, MW, IC50 (µM) if available, and subsite 
location (LHS, RHS, Channel); b) The structure of 14,15-epoxy-5Z,8Z,11Z-
eicosatrienoic acid c) 2D structures of the ligands whose protein conformation (together 
with the apo structure) was used for cross-docking the compounds found in a) – their 
PDB entries, MW, IC50 (µM) if available, and subsite location (LHS, RHS, Channel) 
are also shown;d) 2D structure of Fulvestrant, a potent inhibitor of sEH. 
 
Figure 3. CMIP contours; a) CMIP surface for the +1 charged probe shown in blue for 
the apo structure 5AHX (contour for -7kcal/mol). The catalytic residue D335 (carboxyl 
moiety in red spheres) is shown behind; b)-d) Three generated contours (shown at -
3kcal/mol) with a neutral charge probe shown as white surfaces for three representative 
structures of sEH: b) LHS subsite– 5ALT ; c) RHS subsite – 5ALY; d) Channel 
subsite– 5ALS. In dark blue the K495-V500 loop is shown.  
 
Figure 4. Some examples of binding mode prediction obtained by the cross-docking 
calculations with GLIDE. In all cases, the experimental binding mode of the ligand is 
visualized in brown carbons and tubes whereas the predicted binding mode is visualized 
in green carbons and tubes: a) Complex 5ALY/5AI0; b) Complex 5ALL/5ALX. 
 
Figure 5. PELE simulation profiles for a few selected ligand-protein complexes of 
Table 1. Each graph shows the RMSd distance in Å to the experimental ligand pose on 
the x-axis and the interaction energy in kcal/mol as predicted by PELE during the 
simulations is on the y-axis. Each color and shape in the graphs represents single PELE 
trajectory from a total of 128 in every complex simulation; a) 5ALT when simulated 
against 5AHX (5ALT/5AHX); b) 5AKL/5AHX; c) 5ALS/5AI0; d) 5ALK/5AHX; e) 
5AIC/5AKE; f) 5AM5/5AKE. 
 
Figure 6. Top poses predicted by PELE vs. X-ray crystal poses. PELE docked ligands 
are in light blue carbons (tubes representations), X-ray ligand structures are shown in 
brown carbon colors and tubes. H-bonds are shown in red dashed lines. a) 5ALT ligand 
simulated against the 5AHX structure (5ALT/5AHX); b) 5AKL/5AHX; c) 5ALS/5AI0; 
d) 5ALK/5AHX; e) 5AIC/5AKE; f) 5AM5/5AKE (both pockets).  
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